Last $5.53 USD
Change Today 0.00 / 0.00%
Volume 373.3K
IDIX On Other Exchanges
IDIX is not on other exchanges.
As of 1:41 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

idenix pharmaceuticals inc (IDIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $9.32
52 Week Low
10/31/13 - $2.93
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

idenix pharmaceuticals inc (IDIX) Related Businessweek News

No Related Businessweek News Found

idenix pharmaceuticals inc (IDIX) Details

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company’s HCV discovery program focuses on nucleoside/nucleotide polymerase inhibitors, NS5A inhibitors, protease inhibitors, and non-nucleoside polymerase inhibitors. It is also developing non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency (HIV) virus type-1 and acquired immune deficiency syndrome (AIDS); and products and drug candidates for the treatment of patients with hepatitis B virus (HBV). The company has a collaboration agreement with Janssen Pharmaceuticals, Inc.; Novartis Pharma AG; ViiV Healthcare Company; and GlaxoSmithKline. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

84 Employees
Last Reported Date: 02/27/14
Founded in 1998

idenix pharmaceuticals inc (IDIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $501.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $276.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $347.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2012.

idenix pharmaceuticals inc (IDIX) Key Developments

Idenix Pharmaceuticals Announces Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C

Idenix Pharmaceuticals Inc. announced continued progress of the company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus (HCV) infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log(10) IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January 2014, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-naïve, genotype (GT) 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg -- 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-naïve, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.

Idenix Pharmaceuticals Inc. - Special Call

Idenix Pharmaceuticals Inc. - Special Call

Idenix Pharmaceuticals Inc. Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case

Idenix Pharmaceuticals Inc. announced that it intends to file an appeal to challenge the Oslo, Norway District Court's decision in a patent invalidity case concerning Idenix's co-owned Norwegian patent NO 330 755 that covers certain 2'-methyl-2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus (HCV) and other flaviviridae infections. In September 2012, Gilead Sciences Europe Ltd., a subsidiary of Gilead Sciences Inc. filed a lawsuit in the Court claiming that Idenix's Norwegian patent NO 330 755 is invalid. Idenix subsequently filed a counter claim that a patent owned by Gilead covering similar subject matter (Norwegian patent NO 333 700) is invalid and unenforceable. On March 21, 2014, the Court determined that Idenix's patent is invalid and that Gilead's patent is valid.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDIX:US $5.53 USD 0.00

IDIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $50.60 USD -0.35
GlaxoSmithKline PLC 1,651 GBp +8.50
View Industry Companies

Industry Analysis


Industry Average

Valuation IDIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,580.4x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,518.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDENIX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at